Jailendra Singh, an analyst from Truist Financial, has initiated a new Buy rating on Hinge Health, Inc. Class A (HNGE).
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jailendra Singh has given his Buy rating due to a combination of factors that highlight Hinge Health, Inc.’s strong position in the digital musculoskeletal (MSK) care market. The company is recognized as a leader in this underpenetrated category, addressing a significant portion of the U.S. direct medical spend. Hinge Health’s AI-powered platform effectively overcomes traditional healthcare barriers, serving a vast network of over 20 million contracted lives and maintaining a high client retention rate. Its partnerships with major national health plans and top pharmacy benefit managers further solidify its market presence.
Additionally, Hinge Health demonstrates high visibility growth with an expanding total addressable market across various conditions and geographies. The company boasts impressive clinical outcomes, validated by numerous studies, which translate into a strong return on investment for employers. Singh’s analysis also points to a promising start for the 2026 selling season, with significant client rollouts anticipated. The stock’s current trading multiples, compared to its peers, and the potential for long-term value creation underpin Singh’s $48 price target and Buy rating.
Singh covers the Healthcare sector, focusing on stocks such as Hims & Hers Health, Evolent Health, and Astrana Health. According to TipRanks, Singh has an average return of -15.2% and a 32.13% success rate on recommended stocks.
In another report released today, Barclays also initiated coverage with a Buy rating on the stock with a $43.00 price target.